Angiodynamics Inc (ANGO) · Oct 8, 2026 · Exec change
Eric Honroth appointed CEO — Effective November 2, 2026; $735,000 salary plus 350% inducement award
AngioDynamics’ CEO change is now set: Eric Honroth starts November 2 with a sizable cash and equity package as the company shifts leadership.
AngioDynamics is in the middle of a planned shift toward higher-growth Med Tech platforms—Auryon, mechanical thrombectomy and NanoKnife—after Med Tech grew 18.4% in fiscal 2026 while the broader company continued its strategic transformation. The filing advances that transition by naming Eric Honroth as CEO and President effective November 2, replacing the previously announced open-ended succession process. 〔0〕
The succession direction was already known; the identity and terms are new. AngioDynamics had disclosed in January that Jim Clemmer intended to retire once a successor was appointed, so this is not a surprise that the company is changing CEOs. The new information is that Honroth has been selected and will also be nominated to the board while serving as CEO. That makes the filing more of a completion of a known process than a change in strategic direction. 〔1〕
The company is paying materially to secure the handoff. Honroth receives a $735,000 base salary, a 95% target bonus, an initial long-term incentive award equal to 350% of base salary, a $450,000 equity buyout award and a $350,000 cash sign-on bonus. The package also includes a $24,000 annual automobile allowance and $10,000 per month of commuting and temporary-living support for up to 24 months. 〔2〕 〔3〕 〔4〕 〔5〕
| Compensation element | Filing amount or term |
|---|---|
| Base salary | $735,000 annually |
| Target annual bonus | 95% of base salary |
| Initial inducement award | 350% of base salary |
| Equity buyout award | $450,000 |
| Cash sign-on bonus | $350,000 |
| Automobile allowance | $24,000 annually |
| Commuting allowance | $10,000 monthly for up to 24 months |
| Standard severance | 18 months of base salary plus benefits |
| Change-in-control severance | 24 months of base salary plus target bonus and accelerated equity |
The economics create a real, if limited, complication. The filing locks in substantial upfront compensation and enhanced severance before Honroth has demonstrated results at AngioDynamics. Most of the equity is intended to vest over time or depend on performance, and the sign-on cash is repayable if he leaves voluntarily without good reason or is terminated for cause before his first anniversary, which gives the board some retention protection.
Operationally, this is continuity rather than a reset. The agreement keeps Honroth tied to the existing growth agenda through performance-based incentives and board oversight, but it does not announce a new product strategy, acquisition or change to financial guidance. The key unanswered question is execution: whether the incoming CEO can maintain momentum in the higher-growth platforms while improving the company’s still-unfinished profitability transition.
Bottom line: This is a mostly expected CEO succession now made concrete, with a costly package attached. It matters because leadership execution is central to AngioDynamics’ Med Tech growth plan, but the filing itself changes personnel—not strategy, products or financial targets.
Eric Honroth assumes CEO role, November 2
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!